Heranba IPO Review Analysis

Share This Post

Heranba is an agrochemical company launching its IPO on 23rd Feb 2021. The IPO would close on 25th Feb 2021. The price band for the IPO is Rs 626-Rs 627 per share. Emkay Global and Batlivala and Karani Securities are the BRLM of the IPO. Heranba IPO Review Analysis

Heranba is a crop protection chemical manufacturer, exporter and marketing company based in Vapi, Gujarat. The company launches its IPO on 23rd Feb 2021 worth Rs 625 crore. Offer details are as follows:

Offer Details
Offer Size Rs 625 crore
of which:
Fresh Issue Rs 60 crore
Offer for sale Upto 90,15,000 equity shares amounting to Rs (.) crore
Price Band Rs 626 to Rs 627 per share
Offer Period Feb 23 2021- Feb 25 2021
Offer Structure QIBs: upto 50% of the offer
NIIs: upto 15% of the offer
RIIs : upto 35% of the offer
Market Lot Minimum- 23 shares (Rs 14421)
Maximum- 299 shares (Rs 187473)
Listing on BSE, NSE
BRLM’s Emkay Global Financial Services, Batliwala and Karani Securities
Registrar Bigshare Services Private Limited

Objects of the offer Heranba IPO Review Analysis

  • Funding working capital requirements of the Company (Rs 50 Crore)
  • General corporate purposes

Business Profile

  • Incorporated in 1992, the company manufacture Intermediates, Technicals and Formulations. The company is a leading domestic producers of synthetic pyrethroids like cypermethrin, alphacypermethrin, deltamethrin, permethrin, lambda cyhalothrin etc.
  • Pesticides range includes insecticides, herbicides, fungicides and public health products for pest control.
  • Exports the products to more than sixty countries in Latin America, CIS, Middle East, Africa, Asia and Southeast Asia in Fiscal 2020.

Heranba’s business verticals includes

    1. Domestic Institutional sales of Technicals: manufacturing and selling of Technicals in bulk to domestic companies
    2. Technicals Exports: Exports of Technicals in bulk to customers outside India.
    3. Branded Formulations: Manufacturing and selling of Formulations under our own brands through our own distribution network in India. Some name of these brands is Jayam, Progress Plus, Param, Cypraplus and others.
    4. Formulations Exports: Export of Formulations in bulk and customer-specified packaging outside India.
    5. Public Health: Manufacturing and selling of general insect control chemicals by participating in public health tenders issued by governmental authorities and selling to pest management companies.
  • Has three manufacturing and packaging facilities in and around the industrial belt of Vapi, Gujarat having 174 reactors with an aggregate manufacturing capacity of 14,024 MTPA.
  • The company has an in-house R&D team for product development. Heranba’s new R&D facility shall become operational from Dec 2020. It is in process of developing 2 products of fungicides, 2 products of herbicides and 1 product of Insecticides, for which research and development tests have been initiated, for exclusive sale to the European markets after registration with the regulatory authority in EU.

Financial Highlights

Heranba earned revenues of Rs 619.21 crore in H1FY21. The company’s PAT was Rs 66.31 crore in the corresponding half year. Total revenues reduced marginally by 4% in FY20 to Rs 967.91 crore as against Rs 1011.84 crore in FY19. Though PAT in FY20 improved to Rs 97.75 crore from Rs 75.40 crore in FY19. The decrease in revenues was driven by a fall in sales in the last quarter of FY20 due to the lockdown.

The operating and the net margins show an increasing trend being 15.33%, 13.82% and 12.5% for FY20, FY19 and FY18 respectively. Net margins were 10.10%, 7.45% and 6.25% for the corresponding years.

Return on net worth is strong at 30.47% and 33.04% in FY20 and FY19 respectively.

Peer Comparison and Valuation

Rallis, Bharat Rasayan, Punjab Chemicals, Sumitomo Chemicals are some of the peers of Heranba listed in the RHP. The product offerings of the companies are not identical but they fall under similar business lines.

Heranba is fully priced at P/BV of 6.42x at NAV of Rs 97.63 considering the upper price band of Rs 627. The company’s P/E is 19x (calculated at annualized EPS of H1FY21 of Rs 33.96 per share at upper price band) which is nearly at par with those of its peers.

Peer Comparison Table

Particulars Rallis Sumitomo Bharat Rasayan Punjab Chemicals Heranba
Face Value per share 1 10 10 10 10
Total Income for FY20 (INR Crores) 2286 2435 1231 562 967
EPS (as on 18th Feb 2021) 11.37 6.3 35.28 25.03
NAV per share 72.51 24.48 1327.73 79.72 82.14
Return on net worth 13.11% 16.75% 27.94% 11.00% 30.47%
P/E (as on 18th Feb 2021) 22.9 47.33 26.87 24.29 25.05
P/B (as on 18th Feb 2021) 3.6 12.19 7.17 10.75 7.63
Valuation Parameters EPS P/E NAV P/BV
33.96 19x 97.63 6.42

Future Outlook 

The growing need for pest management in agriculture owing to quality and quantity concerns of agricultural produce is further boosting the demand for agrochemicals across the globe. Also rising awareness towards the efficiency of pyrethroids for use in the control of a wide array of insects with minimal effect on humans, birds, and animals is driving the growth of the pyrethroids market.

It is expected that the global agrochemicals market would grow at a CAGR of 4.11% during 2020-2025, reaching a value of US$ 73.39 billion by 2025.

Heranba is a leader in the pyrethroid segment. It offers a diversified range of products globally.  Increasing revenues, reasonable margins and future growth prospects of the company are the positives for the company. Hence, the investors might consider it for subscribing to the IPO.

You might also be interested in

 RailTel IPO Subscription Status

 

Related Posts


Share This Post
About CA Priyanka Choudhary Jain 69 Articles
Chartered Accountant & an experienced credit analyst. She has worked with CRISIL as a Senior Credit Analyst on rating assignments including business & financial analysis in Corporates as well as the Public Finance Sector. Please mail your queries, feedback, and any suggestions to her on info.financepost@gmail.com

Be the first to comment

Leave a Reply

Your email address will not be published.